PDS Biotechnology Corp — Director's Dealing 2017

Jun 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-06-20

Reporting Person: Conti Kurt G (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-20	Stock Option (right To Purchase)	$10.15	A	15000	Acquired	2027-06-20	Common Stock (15000)	Direct